International audienceTo estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca Department of N...
OBJECTIVE: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical...
ObjectivePaliperidone palmitate is an atypical long-acting injectable (LAI) antipsychotic that has b...
To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting inje...
Abstract Background Patients having chronic schizophrenia with frequent relapses and hospitalization...
Objective: To model the cost effectiveness of paliperidone palmitate (paliperidone long-Acting injec...
Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceut...
Objective: Long-acting injections (LAIs) of paliperidone palmitate have been shown to improve medica...
This study assessed the relative cost-effectiveness of a first generation and a second generation lo...
Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence ...
Purpose: Antipsychotic long-acting injections (AP-LAIs) are indicated for patients affected by schiz...
Objective: Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are kno...
Jörg Mahlich,1,2 Masamichi Nishi,3 Yoshimichi Saito11Health Economics, Janssen Pharmaceutical K...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Background Long-acting injectable (LAI) antipsychotics have been shown to reduce risk of relapse in ...
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca Department of N...
OBJECTIVE: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical...
ObjectivePaliperidone palmitate is an atypical long-acting injectable (LAI) antipsychotic that has b...
To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting inje...
Abstract Background Patients having chronic schizophrenia with frequent relapses and hospitalization...
Objective: To model the cost effectiveness of paliperidone palmitate (paliperidone long-Acting injec...
Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceut...
Objective: Long-acting injections (LAIs) of paliperidone palmitate have been shown to improve medica...
This study assessed the relative cost-effectiveness of a first generation and a second generation lo...
Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence ...
Purpose: Antipsychotic long-acting injections (AP-LAIs) are indicated for patients affected by schiz...
Objective: Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are kno...
Jörg Mahlich,1,2 Masamichi Nishi,3 Yoshimichi Saito11Health Economics, Janssen Pharmaceutical K...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Background Long-acting injectable (LAI) antipsychotics have been shown to reduce risk of relapse in ...
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca Department of N...
OBJECTIVE: A 1-year semi-Markov model was constructed to simulate the cost-effectiveness of atypical...
ObjectivePaliperidone palmitate is an atypical long-acting injectable (LAI) antipsychotic that has b...
DOI
Add to ORKG